T. Gorlia

Discipline

Psychologie (1) Economies et finances (1)

Type de document

Articles (11)

Co-auteur

Date

Source

Mot-clé

survie (11) Survival (11) Patients (11) Patients (11) Treatment (10) Radiotherapy (8) Months (8) Human beings (8) Brain (8) Radiotherapy (8) cerveau (8) procès (7) Methylation (7) Use (7) Methylation (7) thérapie (6) analyse (6) ADN (6) Therapeutics (6) DNA (6) Older people (6) Analysis (6) adulte (5) cancer (5) Chemotherapy (5) Cancer (5) Methods (5) Confidence (5) Chemotherapy (5) Cancer (5)

Documents écrit par T. Gorlia (11) | parle de T. Gorlia (0)

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
M. Klein et al. (5 mai 2021)
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
M.E. Hegi et al. (15 mars 2019)
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
P. Bady et al.
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
W. Wick et al. (1 oct. 2016)
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
M. Weller et al. (22 mars 2016)
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
B.G. Baumert et al. (2016)
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
M.E. Hegi et al. (2012)
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
R. Stupp et al. (2011)
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.
C.P. Beier et al. (2009)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R. Stupp et al.
MGMT gene silencing and benefit from temozolomide in glioblastoma.
M.E. Hegi et al. (2005)